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Of the 189 air toxics listed in the Clean Air Act, a substantial number are important in potentially
causing adverse health effects in several organ systems. Although the major health effects are
manifested as respiratory diseases, especially airways disease, these agents may cause cancer
and premature mortality, probably from cardiopulmonary disease. Validated biologic markers may
be useful in identifying early effects to improve our understanding of exposure-response relation-
ships and clarify susceptibility. However, the knowledge obtained from epidemiologic studies uti-
lizing these new molecular tools will reduce morbidity and mortality from air toxics only when
they can be applied effectively in the prevention and control of disease. Intervention strategies
using these markers can be used to identify etiologic factors and assess the effectiveness of
exposure reduction, and, in some instances, chemoprevention. This paper illustrates examples of
these intervention strategies and reviews the current strengths and limitations of environmental
molecular epidemiology in controlling disease caused by air toxics. Environ Health Perspect
104(Suppl 5):921-925 (1996)
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Introduction
This symposium has described the current
state-of-the-art research on biologic mark-
ers that may be relevant to air toxics. The
goal of such research is practical: to apply
relevant and valid biomarkers ofexposure,
effect, and susceptibility to epidemiologic
studies ofpopulations exposed to air toxics
and to incorporate the resulting informa-
tion into public health actions aimed at
controlling exposures and adverse health
effects. Studies that incorporate the use of
biologic markers in human populations are
often referred to as "molecular epidemio-
logic studies." A conceptual approach to the
application ofbiologic markers to human
populations is shown in Figure 1. The ulti-
mate goal for environmental molecular
epidemiology is to fulfill the promise of
preventive medicine: environmental disease
prevention and control.
Much ofwhat we have learned about
the human health effects oftoxic exposures
has come from epidemiologic studies of
exposed workers and from toxicologic
studies on animals. Astute clinical observa-
tions and animal testing have provided the
basis for large-scale epidemiologic studies
ofworkers exposed to toxic agents such as
asbestos and vinyl chloride. The risk ofdis-
eases caused by such agents are markedly
increased in exposed workers who have
usually been exposed to concentrations
much higher than the general population.
However, in the case of community air
pollution studies, new challenges have
arisen. First, we must find ways to eluci-
date factors that modestly increase disease
risk (1). Though such causes could be
extremely important from a public health
point ofview, these kinds of associations
are difficult to detect in epidemiologic
studies because the relative risk for low-level
exposed, versus nonexposed, people is only
slightly elevated (2). Complicating this
problem is the generic aim ofexposure-dose
assessment in field studies: imprecise
methodology to quantify exposures, espe-
cially those which may have occurred years
ago, can lead to misclassification and bias.
Moreover, the temporal pace ofthe tradi-
tional cohort study, which must await data
from large populations exposed for long
periods, has become an obstacle. Regulators,
clinicians, and the public are too impatient
to await such "natural experiments," and
seek shorter term strategies for studies and
quicker solutions (2).
Since the concept of molecular epi-
demiology was popularized in the early
1980s (3) to describe an evolving approach
to human environmental health research,
much work has been done on biomarker
development. The theoretical foundation
ofthis work relies on three biologic tenets:
a) early biologic effects from a toxic expo-
sure are more prevalent and detectable in
the population at risk than clinical disease is;
b) with technological advances, many toxins
can be either directly quantified in body
fluids or tissues or indirectly measured by
identification of some predictable, dose-
related (early) biological response; and
c) either (or both) of the above may be
influenced by susceptibility phenomena
(heritable or nonheritable), which can also
be accounted for with recent advances in
molecular biology. Combining these three
principles, a newapproach to environmental
health research has emerged that expands on
the traditional epidemiologic paradigm.
In addition to improved measures of
exposure, response, and susceptibility,
side benefits emerge that have direct rele-
vance for intervention (4): contributions
to the understanding ofpathogenic mecha-
nisms at the tissue, cellular, or molecular
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Figure 1. Relationship of biomarkers to exposure, susceptibility, and disease. Adapted from the National Research
Council (36).
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levels, potential for more accurate and eti-
ologic classification of environmental dis-
eases, and the possibility that recognition
of early adverse effects could prompt
strategies for secondary prevention or
disease modification.
Biomarker research does not exist in a
vacuum. Its usefulness can only be real-
ized when it translates into prevention
strategies to protect public health. In this
short review, I describe how biomarkers
may be used in clinical and environmental
interventions.
Intervention Approaches
Intervention approaches in public health
can be characterized as either the high-risk
or population approach (5). The high-risk
approach aims to detect individuals at high
risk by using a biologic marker and lower-
ing risk by clinical intervention or other
action. Usually, the risk marker is moni-
tored concurrently with the intervention.
In contrast, population approach aims to
reduce the overall occurrence ofa risk fac-
tor (exposure) in a population.
Biologic markers may play different
roles in each of these approaches. In the
high-risk approach, a biologic marker is
used to either identify exposure or for early
diagnosis of(preclinical) disease. For exam-
ple, serum cholesterol is an exposure
marker ofrisk indicating biologically effec-
tive dose and can be monitored after phar-
macologic intervention. Other examples of
this approach are shown in Table 1.
An example ofthe population approach
is the prevention of childhood lead accu-
mulation and toxicity by mandating the
removal of lead from gasoline. In this
approach, biomarkers have played an
important role in providing the scientific
basis for regulation-an environmental
preventive, not clinical, intervention.
Biomarkers for lead continued to play an
important role in monitoring the interven-
tion itself, demonstrating decrease popula-
tion lead burden. Other examples of this
approach are shown in Table 2.
In some instances, both high-risk and
population approaches must be employed
Table 1. Examples of high-risk intervention approach.
Problem Intervention
Coronary heart disease Lower cholesterol
Hypertension control
Smoking cessation
Lung cancer Smoking cessation
Radon control in home
simultaneously. Lead toxicity provides an
example ofthis combined approach: regula-
tory measures are concurrently aimed at
reducing the whole population's exposure
and at monitoring internal dose (blood lead)
ofindividual children bypediatricians.
These generic intervention strategies
have also been important in cancer preven-
tion and control, such as control ofoccupa-
tional bladder cancer by substitution of
benzidine dyes with less toxic compounds;
control ofcoke-oven-induced lung cancers
byengineering controls and personal protec-
tion; and control ofbis-chloromethyl ether
induced lung cancer by elimination ofthat
compound in plastic and glass production.
Lung Cancer
Tobacco smoke is implicated in up to 85%
ofthe more than 150,000 lung cancer cases
that occur in the United States every year.
Despite the strong and consistent epidemi-
ologic evidence linking tobacco smoking to
cancer, the majority of smokers do not
develop lung cancer. Individual variability
in carcinogen metabolism may explain dif-
ferential susceptibility to tobacco-induced
lung cancer. In recent years, molecular tech-
niques in the epidemiology of tobacco-
related cancer have been applied in three
areas: determination ofinternal and biologi-
cally effective dose, detection ofearly bio-
logic effects, particularly mutations and
cytogenetic changes, and assessment ofvari-
ations in individual susceptibility to carcino-
gens, mainlyvia metabolic polymorphisms.
Among the 3800 chemicals that have
been identified in tobacco smoke, a large
number are biologically active compounds.
The most important families ofcarcinogens
are polycyclic aromatic hydrocarbons
(PAHs), aromatic amines, nitroso com-
pounds, volatile organic compounds (e.g.,
benzene, formaldehyde), and radioactive
elements such as polonium-210. Chemical
compounds derived from tobacco smoke
have been measured in biological specimens
Table 2. Examples of population intervention approach.
Problem Intervention
Occupational cancer Product substitution
Engineering controls
Lung cancer ETS control
Radon control
Carbon monoxide poisoning Auto emission
Controls
Lead poisoning Removal of lead from
gasoline and paints
ETS, environmental tobacco smoke.
ofsmokers and nonsmokers. DNA adducts
are formed when chemical carcinogens
react with DNA. Several methods of
detecting adducts in lung and surrogate tis-
sue, including the sensitive 32P-postlabeling
procedure for PAHs, have been described in
detail. Among the class ofpulmonary car-
cinogens known as PAHs, benzo[a]pyrene
forms DNA adducts in the lung that are
associated with smoking. Recent research
indicates that surrogate tissue (blood
mononuclear cells) adducts reflect target
organ (lung) adducts in cancer patients
(Figure 2) (6). Such validation will permit
assessment ofinterventions such as smoking
cessation, chemoprevention, and elimina-
tion ofpassive smoking exposures in reduc-
ing PAH-DNA adducts in peripheral
blood mononuclear cells. Use of blood
adducts will also permit epidemiologic
study of large populations exposed to
PAHs in air pollution.
Although the presence of PAH-DNA
adducts has not been definitely associated
with lung cancer, it is clear that these
adducts appear to be important in the
pathway leading to cancer (7), and inter-
ventions aimed at reducing their presence
in high risk individuals are on the horizon.
Focusing on this "upstream" marker of
dose and early effect is particularly impor-
tant in lung cancer prevention, a condition
for which there is no effective early detec-
tion marker and for which treatment is an
ineffective means ofdisease control.
In recent years, mutations in specific
genes can be used as "fingerprints" of
specific exposures, as surrogate end points
of cancer, or for further subtyping of
cancer to clarify causal associations (8).
Epidemiologic evidence suggests the
association between chemical exposure,
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Figure 2. Lung and peripheral blood mononuclear cell
(MNC) PAH-DNA adducts. r=0.74; p<0.001.
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tumor-suppressor gene (p53) and onco-
gene (k-ras) mutation and cancer occur-
rence (9-13). Investigations concerning
the ras oncogene family or the p53 tumor-
suppressor gene have considered the associ-
ation between lung cancer and tobacco
smoking. Results of these studies suggest
that the mutational spectrum of lung
cancer depends on whether the person was
a smoker and whether the person was
exposed to asbestos (14).
Genetic susceptibility to lung cancer has
been examined in a number ofepidemio-
logic studies that incorporate molecular
markers ofsusceptibility to carcinogens. It
has been known for over 30 years that
smoking and family history are independent
risk factors for lung cancer risk (15).
Additional evidence has been provided by
the study ofmetabolic polymorphisms, i.e.,
the different ability to metabolize chemical
carcinogens. Traditional monogenic suscep-
tibility to cancer is related to rare diseases
(e.g., xeroderma pigmentosa, Li-Fraumeni
syndrome) or small subgroups ofcommon
diseases (e.g., BRCA1 in familial breast
cancer) and involves rare mutations that can
be identified through linkage analysis.
Polygenic susceptibility involves frequently
occurring genetic polymorphisms, confers a
low to medium elevation ofrisk for frequent
diseases, and is identified through epidemio-
logic (usually case-control) studies.
Examples ofthis include the CYP2D6poly-
morphism phenotype and lung cancer risk
(16) in whites and the CYPlA] and
GSTMI polymorphisms in lung and bladder
cancer, respectively, amongJapanese (17).
Recent work in the United States sug-
gests that GSTM1 persons with low
dietary intake of antioxidants are at high
risk of squamous cell carcinoma of the
lung, in contrast to persons with null geno-
type and high antioxidant intake (18),
after controlling for smoking intensity,
duration, age, and time since quitting
smoking. This kind of investigation may
lead to antioxidant chemoprevention in ex-
smokers and illustrates a dual clinical
approach to disease control: exposure cessa-
tion combined with cumulative risk
modification on the secondary level. If
genotype-lung cancer risk is modified by a
factor amenable to intervention, such as
dietary intake of antioxidants (19), then
dietary changes and/or supplementation
may be a useful intervention strategy for
individuals who are attempting to quit or
have already quit smoking.
Tobacco smoke contains significant
amounts of another class of carcinogens,
aromatic amines (20). Those compounds
have been shown to be associated with blad-
der cancer in smokers (21). Epidemiologic
studies have suggested that the type of
tobacco associated with the highest risk of
bladder cancer (air-cured tobacco) is also
richer in arylamines and that smokers of
air-cured tobacco have higher levels of
4-aminobiphenyl-hemoglobin adducts in
their blood compared with smokers of
flue-cured tobacco (22). Some arylamines
(including 4-aminobiphenyl and 13-2-
naphthylamine) are among the most
potent human carcinogens. Measurement
of 4-aminobiphenyl-hemoglobin adducts
provides evidence of another biologically
effective dose marker used in epidemio-
logic investigation.
Another common polymorphic trait in
humans, the N-acetylation phenotype, mod-
ulates the concentration of 4-amino-
biphenyl-hemoglobin adducts in both
smokers and nonsmokers (23). The N-
acetyltransferase (NAT) polymorphism has
been associated with bladder cancer in epi-
demiologic studies. NAT is a noninducible
enzyme that deactivates aromatic amines
(24). The slow acetylator genotype preva-
lence is about 50% in the white population.
Slow acetylators exposed to aromatic amines
have been reported to have an increased risk
ofbladder cancer, as well as higher levels of
4-aminobiphenyl adducts (25,26).
Nonmalignant Respiratory
Disease:Asthma
During the last decade, a number ofobser-
vations have raised the public health com-
munity's interest in asthma: a widespread
impression that asthma prevalence has
increased in all age groups, dramatic
increases in hospital admissions for asthma,
an increase in asthma severity despite
improved treatments, relatively abrupt
changes in the prevalence and nature of
asthma in some populations, and an
increase in reported asthma mortality from
several countries (27). Despite difficulties
in defining asthma epidemiologically, there
is some evidence to suggest that the true
prevalence of asthma has been increasing
overall, and there is strong evidence to sup-
port an increasing prevalence in developing
countries and migrant populations. Asthma
appears to be more prevalent in Australia,
New Zealand, Canada, and England than
in the United States and Scandinavia. The
role of air pollution (outdoor and indoor)
in the etiology, severity, and progression of
asthma is a topic of active investigation in
many countries today.
Asthma in children is associated with
atopy, family history, male gender, parental
(especially maternal) smoking, and possibly
with acute respiratory illness in childhood.
Genetic susceptibility to asthma is best
understood by studing its principal under-
lying co-morbid conditions for which we
have phenotype markers: a hypersensitive
state or atopy. Atopic individuals suffer
from rhinitis, eczema, and the asthma syn-
drome. Up to 90% ofasthmatics between
ages 5 and 40 are atopic (28).
The central feature ofatopic-associated
bronchial asthma is the prolonged produc-
tion of IgE to common inhaled antigens
principally triggered by interleukin 4 (IL-
4) and T- and B-lymphocyte interaction
(29). IgE (molecular weight 190 kDa) is
unique among the immunoglobulins in
having a site at its Fc region with a high
affinity for mast cells (which have a high-
affinity IgE receptor), but also affinity (via
low-affinity receptors) on T- and B-lym-
phocytes, monocytes and eosinophils (30).
Allergen-specific IgE, bound to mast cells
in the bronchial epithelium, reacts with its
target antigen, resulting in activation and
degranulation ofthe mast cell. This results
in the release ofa number ofsubstances that
cause the immediate inflammatory response,
including histamine, prostaglandin PGD2,
and leukotrienes, including LTE4 (slow-
reacting substance ofanaphylaxis) (31). The
late-phase bronchial inflammatory response
is associated with influx ofCD4 T-lympho-
cytes and eosinophils (32), which may be
partly recruited by release ofIL-4 from acti-
vated mast cells. Activated T-lymphocytes
recruit and activate eosinophils bya number
of chemokines, especially IL-3 and IL-5
(33). The eosinophils release a number of
products which further activate mast cells.
Eosinophils also release a range of potent
mediators, including platelet-activating fac-
tor, leukotrienes, and prostaglandins, and
activate radicals, which contribute to further
inflammatory change (34).
Asthma is an inflammatory airway dis-
order, and the airway response to allergens
is mediated through complex mechanisms
involving airway inflammation. Current
environmental asthma research has focused
on how pollutants influence acute airway
inflammatory responses in individuals with
different host characteristics, including air-
way responsiveness, IgE antibody isotype,
and major histocompatibility complex class
II allotypes. We need to understand how
host factors modify an individual's acute
airways response to air pollutants. For
example, host factors characteristic ofatopy
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may contribute to up-regulation of and
modification ofthe inflammatory response
to nonantigenic pollutants (and vice versa).
There are biomarkers ofsusceptibility
and effect available in the study ofasthma.
Investigation ofthe genetic susceptibility of
atopic asthma has led to direct assay ofIgE
responsiveness. Measurement of total
serum IgE by solid-phase immunoassay
offers one method ofhigh-risk phenotype
analysis. Altered structure/function can be
easily measured using standardized
bronchial challenge testing with histamine
or methacholine.
Baseline (preexposure) airway hyperre-
sponsiveness may modify the airway
response to pollutants, leading to an
altered inflammatory response, which in
turn may lead to a positive feedback loop
whereby the altered inflammatory response
further increases airway reactivity.
Repeated episodes of pollutant exposure
may subsequently lead to airway hyperre-
sponsiveness and clinical asthma. A possi-
ble mechanism of this proposed feedback
phenomenon is that increased airway
responsiveness, as well as other host fac-
tors, may modulate the intensity and
composition of the cellular infiltrate in
the airways after pollutant exposure.
A second possible mechanism ofpollu-
tant-associated airway hyperresponsiveness
was suggested by Fujimaki et al. (35), who
showed that, in mice, inhaled particulate
pollutants enhance or stimulate IgE anti-
body production. Fly ash and aluminum sil-
icate instilled to the lung acted as adjuvants
forproduction ofIgE and IgG antibody.
Even as our knowledge of the patho-
genesis of asthma increases, additional
areas ofuncertainty continue to arise. The
complex interaction between pollutants,
allergens, and host characteristics in asthma
remain unclear. However, mechanistic
research has expanded the range ofpoten-
tial biomarkers available for the study of
asthma and air pollution. Borrowing from
the paradigm used for cancer, these are
obvious parallels in the research approach
that can be used to elucidate the causal
pathway between exposure and asthma.
Clarifying these events may help to guide
environmental interventions aimed at min-
imizing exposure to the whole popultion
and guide clinical interventions focused at
high-risk individuals.
Conclusions
Current biomarker research in environ-
mental health has fostered the development
of a new research endeavor, molecular epi-
demiology, which expands upon the tradi-
tional toxicologic or epidemiologic research
paradigms. This development has led to
exciting opportunities in environmental
health research, which will add greatly to
our understanding of the human health
effects oftoxic exposures. However, much
more basic research in environmental mol-
ecular epidemiology needs to be accom-
plished before effective environmental and
clinical interventions can be instituted for
diseases such as cancer and neurologic dis-
orders. The basis ofsuch interventions will
be exposure-disease associations, dose-
response relationships, detection of early
pathophysiological effects ofexposure, and
gene-environment interactions. Realiz-
ation of our goal to prevent disease from
air toxics will require expanded multidisci-
plinary research efforts in both toxicology
and epidemiology.
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